ADAM17
ADAM17
ADAM17, also known as tumor necrosis factor-α converting enzyme (TACE), is an enzyme that in humans is encoded by the ADAM17 gene. This enzyme belongs to the ADAM family, which is a group of peptidases known for their role in the shedding of membrane-anchored proteins. ADAM17 is particularly important in the regulation of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α).
Function
ADAM17 is a membrane protein that cleaves several membrane-bound cytokines, growth factors, receptors, and other proteins. Its most notable substrate is TNF-α, a cytokine involved in systemic inflammation and a member of a group of cytokines that stimulate the acute phase reaction. By cleaving the membrane-bound precursor of TNF-α, ADAM17 releases the soluble form of this cytokine, which is a key player in inflammatory processes.
Besides TNF-α, ADAM17 also acts on substrates like transforming growth factor-α (TGF-α), L-selectin, and amyloid precursor protein. Through the shedding of these molecules, ADAM17 regulates various biological processes including cell proliferation, adhesion, and migration.
Structure
ADAM17 is a type I transmembrane protein and consists of a prodomain that maintains the enzyme in an inactive state until it is removed, a metalloprotease domain that contains the catalytic site, a disintegrin domain, a cysteine-rich domain, and a cytoplasmic domain. The metalloprotease domain of ADAM17 contains a zinc-binding site essential for its proteolytic activity.
Clinical Significance
Given its role in shedding TNF-α and other regulatory molecules, ADAM17 has been implicated in various pathological conditions including cancer, rheumatoid arthritis, and Alzheimer's disease. Inhibitors of ADAM17 are being studied for their potential to treat these diseases by controlling the bioavailability of TNF-α and other growth factors.
Genetic Studies
Mutations in the ADAM17 gene have been associated with inflammatory diseases and certain cancers, highlighting the importance of regulated proteolysis in human health.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD